Dalbavancin

Dalbavancin (BI-397), a novel second-generation lipoglycopeptide antibiotic, possesses in vitro activity against a variety of Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE), Dalbavancin inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 μg/mL and 0.25 μg/mL, respectively

[H][C@@]1(Oc2c3Oc4ccc(C[C@@]5([H])NC(=O)[C@H](NC)c6ccc(O)c(Oc7cc(O)c(Cl)c(c7)[C@]([H])(NC5=O)C(=O)N[C@]5([H])c(c3)cc2Oc2ccc(cc2Cl)[C@@H](O)[C@]2([H])NC(=O)[C@]([H])(NC5=O)c3ccc(O)c(c3)-c3c(O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]5O)cc(O)cc3[C@H](NC2=O)C(=O)NCCCN(C)C)c6)cc4)O[C@@H]([C@@H](O)[C@H](O)[C@H]1NC(=O)CCCCCCCCC(C)C)C(O)=O